BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33741175)

  • 1. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
    Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
    Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 33741175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
    Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
    Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 36166247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
    Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
    Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
    Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
    Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
    Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
    Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
    PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
    Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
    J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
    Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
    PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
    Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
    PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glomerular Galactose-Deficient IgA1(KM55) Positive May Predict Poorer Prognosis in Coexisting Primary Membranous Nephropathy and IgA Nephropathy Patients.
    Cheng W; Wang G; Guo W; Sun L; Xu X; Dong H; Ye S; Geng Y; Cheng H
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
    Zhang X; Xie X; Shi S; Liu L; Lv J; Zhang H
    Nephrol Dial Transplant; 2020 Dec; 35(12):2117-2123. PubMed ID: 31377786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
    PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1.
    Yamasaki K; Suzuki H; Yasutake J; Yamazaki Y; Suzuki Y
    Monoclon Antib Immunodiagn Immunother; 2018 Dec; 37(6):252-256. PubMed ID: 30570353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
    Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
    BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.
    Tang M; Zhang X; Li X; Lei L; Zhang H; Ling C; Ni J; Lv J; Liu X; Chen X
    Clin Exp Nephrol; 2021 Jan; 25(1):37-43. PubMed ID: 32935202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.
    Zhang M; Zhou W; Liu S; Zhang L; Ni Z; Hao C
    Nephron; 2021; 145(3):225-237. PubMed ID: 33596564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.
    Ishiko S; Horinouchi T; Fujimaru R; Shima Y; Kaito H; Tanaka R; Ishimori S; Kondo A; Nagai S; Aoto Y; Sakakibara N; Nagano C; Yamamura T; Yoshimura M; Nakanishi K; Fujimura J; Kamiyoshi N; Nagase H; Yoshikawa N; Iijima K; Nozu K
    Sci Rep; 2020 Aug; 10(1):14026. PubMed ID: 32820208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
    Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
    PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.
    Temurhan S; Akgul SU; Caliskan Y; Artan AS; Kekik C; Yazici H; Demir E; Caliskan B; Turkmen A; Oguz FS; Sever MS
    Transplant Proc; 2017 Apr; 49(3):541-545. PubMed ID: 28340830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.